VLA — Valneva SE Share News
0.000.00%
Last trade - 00:00- €440.83m
- €529.53m
- €174.66m
Valneva secures new debt facility, revises outlook
Valneva tops SBF 120 on long-term efficacy of IXCHIQ vaccine
Live Markets: Europe before the bell: Muted start as Q3 wraps up
Brief: Valneva Reports 95% Seroresponse Four Years After IXCHIQ Vaccination
Valneva rises after Lyme disease vaccine study data
Brief: Valneva Announces Positive Immunogenicity And Safety Data For Lyme Vaccine
Valneva shares hit by FDA suspension of IXCHIQ vaccine
Valneva shares tumble after suspension of U.S. chikungunya vaccine licence (updated)
FDA suspends Valneva's chikungunya vaccine license in the U.S.
Brief: Valneva's IXCHIQ Authorized In Canada For People Aged 12 And Older
Valneva tops SBF120 after 'solid' results
Brief: Valneva H1 Adjusted EBITDA Negative EUR 6 Mln
Brief: Valneva: FDA Lifts Temporary Pause Recommendation On Use Of IXCHIQ In Elderly
Bavarian Nordic jumps after it confirms talks on potential takeover
Bavarian Nordic jumps after media report on potential bid
Valneva rises after EMA lifts temporary restriction on chikungunya vaccine
French and Benelux stocks-Factors to watch
Brief: Valneva Announces Lifting Of EMA's Temporary Restriction On Use Of Chikungunya Vaccine IXCHIQ® In Elderly
Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults